Mitchell Stark

Associate Professor Mitchell Stark is a molecular biologist and Group Leader (Principal Research Fellow) from the Dermatology Research Centre (DRC) based at the Frazer Institute, The University of Queensland (UQ; Brisbane, Australia). He leads the pre-melanoma genomics program at the Frazer Institute and his group has extensive experience in the use of next-generation sequencing, spatial transcriptomics, bioinformatics, and functional analysis for a variety of applications. The Stark Lab’s major research streams include: miRNA biomarkers for melanoma progression and the development a Genomics Atlas of pre-skin cancer lesions, which aim to provide to greater understand melanoma progression from naevi and early invasive melanoma, with a goal to discover novel predictive biomarkers that offer increased precision to the clinical management of patients.

He has been engaged in melanoma and nevus research for 25+ years (with 9-years post PhD) and over this time he has been working towards understanding the aetiology of melanoma, studying gene dysregulation during tumor progression along with predisposition to melanoma in families with high risk for melanoma development. Dr Stark has a total of 97 career publications including 1 book chapter, 83 journal articles, 12 reviews/perspectives and 1 patent (WO/2016/029260) which have been cited a total of 7,053/10,208 times (Scopus/Google; h-index: 38/42) and has published in respected journals such as Nature, Nature Genetics, Cancer Research, and Journal of Investigative Dermatology. He has been awarded a career total of ~$10M as an Investigator (PI/co-PI/co-Investigator) including a prestigious NHMRC Peter Doherty Early Career Research Fellowship (2016-2019) and a recent NHMRC Investigator award (2025-2029), along with several research grants as Principal Investigator (e.g., Advance QLD Innovation Partnership, Department of Defence CDMRP – Melanoma Research Program).